课题基金 / 基金详情

Impact of Fc N-glycan structure on HIV-specific antibody functions

Impact of Fc N-glycan structure on HIV-specific antibody functions
Fc N-聚糖结构对 HIV 特异性抗体功能的影响
批准号:
9322012
负责人:
Donald L. Jarvis
金额:
$74.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-01 至 2020-07-31

项目摘要

项目成果

Donald L. Jarvis的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(申请人提供):艾滋病毒感染对人类健康具有重大的世界性影响。尽管到目前为止,我们无法开发出一种高效的疫苗,但我们仍然相信,接种疫苗可以控制艾滋病毒的流行。一种高效的疫苗可能会诱导广泛的中和抗体(BNAbs),可以中和不同的艾滋病毒分离株,类似于一些长期控制艾滋病毒感染的患者产生的抗体1,2。这种疫苗还可能诱导具有强大效应功能的非中和抗体(NNAbs),可以降低艾滋病毒感染的风险,类似于RV144疫苗试验3-5中的一些受试者产生的抗体。在疫苗开发的同时,人们认为我们 可以制造和被动地给予bNAbs和/或nNAbs,用于暴露后预防或作为抗逆转录病毒治疗的辅助手段,特别是针对耐药病毒。广泛中和不同艾滋病毒变种的能力和诱导有效的效应器功能都是艾滋病毒特异性抗体(HIV-Abs)控制感染能力的关键因素。在TURE中,已知Fc受体(FCR)介导的效应器功能的效力取决于Ig G N-糖链结构7。不幸的是,我们没有关于Fc糖基化在HIV感染的整体免疫反应中对相关HIV-Ab功能的影响的全面信息。显然,最近的一些研究已经取得了突破性进展,提供了重要的见解,并激发了人们对这一领域的极大兴趣。但是,他们也证明了需要进一步分析更广泛的糖形式选择,N-糖链结构对HIV-Abs阻断粘膜传播的能力的影响,以及在允许HIV感染的临床前动物模型中不同糖形式的总体保护效果。我们建议通过更全面地分析N-糖链结构在HIV感染的整体免疫应答中对HIV-Abs的体外和体内功能的影响来实现这些目标。我们将使用VRC01和A32作为功能性血糖研究的模型,旨在研究迄今为止报道的所有研究中使用的最广泛的一套分析方法中最广泛的糖形式选择。我们将评估八种不同的N-糖基化特征对VRC01和A32功能的影响,包括病毒中和(VRC01)和效应器功能(均为HIV-Abs)。我们还将评估不同VRC-01和/或A32糖型的选定子集在HU-BLT小鼠(临床前动物模型系统)中预防HIV粘膜传播的总体能力。结果将揭示基于N-葡聚糖的机制,调节由两个功能不同的HIV-Abb驱动的免疫反应,并确定一个或多个特定的糖型作为HIV疫苗诱导和/或在人类治疗应用之前进行重组制造的最佳靶点。
英文摘要
 DESCRIPTION (provided by applicant): HIV infections have a significant worldwide impact on human health. Despite our inability to develop a highly effective vaccine to date, it is still widey believed that vaccination could control the HIV pandemic. A highly effective vaccine might induce broadly neutralizing antibodies (bNAbs) that can neutralize diverse HIV isolates, analogous to those produced by some patients with long-term control over HIV infection1,2. This vaccine would probably also induce non-neutralizing antibodies (nNAbs) with potent effector functions that can reduce the risk of HIV infection, analogous to those produced by some subjects in the RV144 vaccine trial3-5. In parallel with vaccine development, it is thought that we can manufacture and passively administer bNAbs and/or nNAbs for post-exposure prophylaxis or as an adjunct to antiretroviral therapy, particularly against resistant viruses. The ability to broadly neutralize different HIV variants and induce potent effector functions are both critically important factors in the ability of HIV-specific antibodies (HIV-Abs) to control infection6. In tur, the potency of Fc receptor (FcR)-mediated effector functions is known to depend upon IgG N-glycan structure7. Unfortunately, we do not have comprehensive information on the impact of Fc glycosylation on relevant HIV-Ab functions in the overall immune response to HIV infection. Clearly, some recent studies have broken ground, provided important insights, and stimulated great interest in this area8-12. But, they also demonstrated the need for further analysis of a broader selection of glycoforms, of the impact of N-glycan structure on the ability of HIV- Abs to block mucosal transmission, and of the overall protective efficacy of different glycoforms in preclinical animal models permissive for HIV infection. We propose to achieve these goals in a more comprehensive analysis of the impact of N-glycan structure on the in vitro and in vivo functions of HIV-Abs in the overall immune response to HIV infection. We will use a VRC01 and A32 as models for functional glycomic studies designed to examine the broadest selection of glycoforms in the broadest set of assays used in any study reported to date. We will assess the impact of eight distinct N-glycosylation profiles on VRC01 and A32 functions, including viral neutralization (VRC01) and effector functions (both HIV-Abs). We also will assess the overall abilities of a selected subset of different VRC-01 and/or A32 glycoforms to protect against mucosal transmission of HIV in the hu-BLT mouse, a preclinical animal model system. The results will reveal N-glycan- based mechanisms modulating the immune responses driven by two functionally distinct HIV-Abs and identify one or more specific glycoforms as optimal targets for induction by an HIV vaccine and/or for recombinant manufacturing in advance of human therapeutic applications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the cellular mechanisms of prion propagation and clearance for devisi
  • 批准号:
    8663969
  • 项目类别:
  • 资助金额:
    $30.64万
  • 财政年份:
    2012
  • 负责人:
    Donald L. Jarvis
  • 依托单位:
Elucidating the cellular mechanisms of prion propagation and clearance for devisi
  • 批准号:
    9070005
  • 项目类别:
  • 资助金额:
    $30.95万
  • 财政年份:
    2012
  • 负责人:
    Donald L. Jarvis
  • 依托单位:
Elucidating the cellular mechanisms of prion propagation and clearance for devisi
  • 批准号:
    8847411
  • 项目类别:
  • 资助金额:
    $30.95万
  • 财政年份:
    2012
  • 负责人:
    Donald L. Jarvis
  • 依托单位:
Elucidating the cellular mechanisms of prion propagation and clearance for devisi
  • 批准号:
    8465922
  • 项目类别:
  • 资助金额:
    $29.87万
  • 财政年份:
    2012
  • 负责人:
    Donald L. Jarvis
  • 依托单位:
海外基金